TRACON Pharmaceuticals Inc
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 Ig… Read more
TRACON Pharmaceuticals Inc (TCON) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: 0.896x
Based on the latest financial reports, TRACON Pharmaceuticals Inc (TCON) has a cash flow conversion efficiency ratio of 0.896x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.77 Million) by net assets ($-3.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
TRACON Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how TRACON Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
TRACON Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TRACON Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Panaxia Labs Israel Ltd
TA:HROD
|
0.052x |
|
K-W
NYSE:K-W
|
N/A |
|
TRIPADVISOR
BE:T6A
|
-0.046x |
|
Kalium Lakes Ltd
AU:KLL
|
0.761x |
|
VILKYSKIU PIENINE (UDW.SG)
STU:UDW
|
0.103x |
|
Centrais Electricas Brasileiras S.A.- Eletrobr?!s American Depositary Shares (Each representing one Preferred Share)
NYSE:EBRB
|
-0.002x |
|
FRBP
PINK:FRBP
|
0.008x |
|
African Agriculture Holdings Inc
NASDAQ:AAGRW
|
0.078x |
Annual Cash Flow Conversion Efficiency for TRACON Pharmaceuticals Inc (2012–2023)
The table below shows the annual cash flow conversion efficiency of TRACON Pharmaceuticals Inc from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-809.00K | $3.68 Million | -4.544x | -223.84% |
| 2022-12-31 | $-7.15 Million | $-26.24 Million | 3.669x | +290.43% |
| 2021-12-31 | $11.71 Million | $-22.57 Million | -1.927x | -183.47% |
| 2020-12-31 | $25.07 Million | $-17.04 Million | -0.680x | +92.25% |
| 2019-12-31 | $2.70 Million | $-23.65 Million | -8.766x | -510.58% |
| 2018-12-31 | $21.44 Million | $-30.78 Million | -1.436x | -84.15% |
| 2017-12-31 | $16.99 Million | $-13.24 Million | -0.780x | +18.63% |
| 2016-12-31 | $28.34 Million | $-27.15 Million | -0.958x | -54.89% |
| 2015-12-31 | $30.98 Million | $-19.16 Million | -0.619x | -1032.13% |
| 2014-12-31 | $-32.17 Million | $1.76 Million | -0.055x | -120.76% |
| 2013-12-31 | $-25.34 Million | $-6.67 Million | 0.263x | -14.41% |
| 2012-12-31 | $-17.66 Million | $-5.43 Million | 0.307x | -- |